Patents Issued in March 7, 2017
-
Patent number: 9585837Abstract: The present invention relates to thermally, stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of ?40° C., and are free from a variation in particle size after 9 months in storage at a temperature of ?40° C. to ?15° C.Type: GrantFiled: April 6, 2011Date of Patent: March 7, 2017Assignee: DSM IP ASSETS B.V.Inventors: Jimbin Mai, Micah Hazzy Needham, Gang Su, Wei Wang-Nolan, Chia-Ping Charles Hsu
-
Patent number: 9585838Abstract: Multivesicular liposomes are prepared at commercial scales by combining a first w/o emulsion with a second aqueous solution to form a w/o/w emulsion using a static mixer. Solvent is removed from the resulting emulsion to form multivesicular liposome-containing compositions. Further optional process steps include primary filtration and secondary cross-flow filtration. The products produced according to the processes of the invention can be produced through a series of aseptic steps.Type: GrantFiled: February 25, 2007Date of Patent: March 7, 2017Assignee: Pacira Pharmaceuticals, Inc.Inventors: Hartoun Hartounian, Dagmar Meissner, Clint B. Pepper
-
Patent number: 9585839Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry powder in a dry powder inhaler.Type: GrantFiled: October 10, 2013Date of Patent: March 7, 2017Assignee: VECTURA LIMITEDInventors: John Nicholas Staniforth, David Alexander Vodden Morton
-
Patent number: 9585840Abstract: Nanoparticles disclosed in the invention comprise a dextran-coated crystalline structure of cerium oxide wherein tetravalent Ce4+ predominates over trivalent Ce3+ and wherein said nanoparticles have a diameter of approximately from 3 to 5 nm. The nanoparticles exhibit both superoxide dismutase activity and catalase activity in an environment having a substantially neutral or acidic pH. The nanoparticles may be used to make and may be contained in a medication. The subject nanoparticles are useful in a method of promoting a cytotoxic anti-invasive effect on squamous tumor cells and inhibit tumor invasiveness.Type: GrantFiled: July 13, 2012Date of Patent: March 7, 2017Assignee: University of Central Florida Research Foundation, Inc.Inventors: Peter Brenneisen, Sudipta Seal, Ajay Karakoti
-
Patent number: 9585841Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.Type: GrantFiled: October 24, 2013Date of Patent: March 7, 2017Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 9585842Abstract: The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nanoparticle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method.Type: GrantFiled: April 28, 2014Date of Patent: March 7, 2017Assignee: SALMON PHARMA GMBHInventors: Akif Emre Tuereli, Bernd Baumstuemmler, Richard Ammer
-
Patent number: 9585843Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: April 19, 2016Date of Patent: March 7, 2017Assignee: Osmotica Kereskedelmi es Szoloaltato KftInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 9585844Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic or prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.Type: GrantFiled: June 29, 2015Date of Patent: March 7, 2017Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 9585845Abstract: A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm.Type: GrantFiled: January 11, 2016Date of Patent: March 7, 2017Assignee: Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.Inventors: Weidong Sun, Fengxiao Ren
-
Patent number: 9585846Abstract: The present invention relates to an anti-microbial composition and method of use thereof. In particular, the present invention relates to an anti-microbial composition comprising farnesol and cetrimide.Type: GrantFiled: September 8, 2014Date of Patent: March 7, 2017Assignee: Wild ChildInventor: John Found
-
Patent number: 9585847Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.Type: GrantFiled: September 10, 2014Date of Patent: March 7, 2017Assignee: Baylor College of MedicineInventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
-
Patent number: 9585848Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.Type: GrantFiled: September 10, 2014Date of Patent: March 7, 2017Assignee: Baylor College of MedicineInventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
-
Patent number: 9585849Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.Type: GrantFiled: April 17, 2007Date of Patent: March 7, 2017Assignee: The Burlington HC Research Group, Inc.Inventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
-
Patent number: 9585850Abstract: The present invention is directed to a method of treating Parkinson's disease using arylcyclopropylamine compounds. The arylcyclopropylamine compounds have the following formula wherein R1, R2, R3, R4, R5 and R6 are described herein.Type: GrantFiled: October 14, 2014Date of Patent: March 7, 2017Assignee: Duke UniversityInventors: Dewey G. McCafferty, Julie A. Pollock, David M. Gooden, Marc G. Caron, Raul R. Gainetdinov, Tatyana D. Sotnikova
-
Patent number: 9585851Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.Type: GrantFiled: April 24, 2012Date of Patent: March 7, 2017Assignee: Palo Alto InvestorsInventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Patent number: 9585852Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.Type: GrantFiled: December 1, 2014Date of Patent: March 7, 2017Inventors: Gad Gilad, Varda Gilad
-
Patent number: 9585853Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.Type: GrantFiled: November 5, 2015Date of Patent: March 7, 2017Assignee: GENFITInventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
-
Patent number: 9585854Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.Type: GrantFiled: November 6, 2013Date of Patent: March 7, 2017Assignee: IASOMAI ABInventors: Thomas Lundeberg, Tiziana Parasassi, Eugenia Pittaluga, Roberto Brunelli
-
Patent number: 9585855Abstract: The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.Type: GrantFiled: March 11, 2014Date of Patent: March 7, 2017Assignee: The University of Utah Research FoundationInventor: Tianxin Yang
-
Patent number: 9585856Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: April 6, 2016Date of Patent: March 7, 2017Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 9585857Abstract: This invention relates to pharmaceutical composition and methods of using vitamin A and/or RARB agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.Type: GrantFiled: January 17, 2014Date of Patent: March 7, 2017Assignee: Cornell UniversityInventors: Lorraine J Gudas, Yannick Benoit, Ronald Perez, Xiao-Han Tang, Steven Trasino
-
Patent number: 9585858Abstract: The present invention relates to a pharmaceutical composition containing 13 compounds: 1,3-diolein, 1-linolein-3-olein, 1,2-diolein, 1-olein-2-linolein, 1,2-dilinolein, trilinolein, 1-olein-2,3-dilinolein, 1-palmitin-2,3-dilinolein, 1,3-diolein-2-linolein, 1-palmitin-2-linolein-3-olein, 1,3-dipalmitin-2-linolein, triolein and 1-palmitin-2,3-diolein. The invention also relates to pharmaceutical preparations of this composition and the use thereof in the treatment of tumors and in the immuno-enhancement.Type: GrantFiled: June 8, 2015Date of Patent: March 7, 2017Assignee: ZHEJIANG KANGLAITE GROUP CO., LTD.Inventor: Dapeng Li
-
Patent number: 9585859Abstract: In various embodiments, the present invention provides methods of lowering triglycerides in subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl, the methods comprising administering to the subject a composition comprising ethyl eicosapentaenoate.Type: GrantFiled: September 25, 2014Date of Patent: March 7, 2017Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
-
Patent number: 9585860Abstract: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.Type: GrantFiled: October 21, 2014Date of Patent: March 7, 2017Assignee: The William M. Yavbrough FoundationInventor: Michael E. Silver
-
Patent number: 9585861Abstract: Gold(III) complexes with mixed ligands as anticancer agents. The gold(III) cations are coordinated to bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and a 1,3-propylenediamine ligand. The diaminocyclohexane ligand can exist in both cis- and trans- configurations, resulting in isomeric gold(III) complexes. Also described are pharmaceutical compositions incorporating the gold(III) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis.Type: GrantFiled: September 30, 2016Date of Patent: March 7, 2017Assignee: King Fahd University of Petroleum and MineralsInventors: Said Al-Jaroudi, Muhammad Altaf, Abdulaziz Al-Saadi, Anvarhusein Abdulkadir Isab
-
Patent number: 9585862Abstract: The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.Type: GrantFiled: May 21, 2012Date of Patent: March 7, 2017Assignee: SK CHEMICALS CO., LTD.Inventors: Yong-youn Hwang, Won-Jae Choi, Jae-Sun Kim, Won-No Youn, Yeo-Jin Park, Joon-gyo Oh, JongSeob Im
-
Patent number: 9585863Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.Type: GrantFiled: May 9, 2016Date of Patent: March 7, 2017Assignees: Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
-
Patent number: 9585864Abstract: This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.Type: GrantFiled: April 14, 2015Date of Patent: March 7, 2017Assignee: National Dong Hwa UniversityInventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin
-
Patent number: 9585865Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: GrantFiled: December 8, 2014Date of Patent: March 7, 2017Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Holger Zinke
-
Patent number: 9585866Abstract: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.Type: GrantFiled: March 4, 2015Date of Patent: March 7, 2017Assignee: The Procter & Gamble CompanyInventor: Christine Marie Cahen
-
Patent number: 9585867Abstract: A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery system which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood for immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery system to induce an incapacitating or immobilizing dose of the formulation at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing the formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration.Type: GrantFiled: August 6, 2015Date of Patent: March 7, 2017Inventor: Charles Everett Ankner
-
Patent number: 9585868Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.Type: GrantFiled: January 15, 2015Date of Patent: March 7, 2017Assignee: NAPO PHARMACEUTICALS, INC.Inventors: William Forbes, Enoch Bortey, Steven King, Pravin Chaturvedi
-
Patent number: 9585869Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein X, Y, Z, R, R1, R2, R3, R?3 R4, R5, R6, R7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.Type: GrantFiled: February 5, 2015Date of Patent: March 7, 2017Assignee: NEWRON PHARMACEUTICALS, S.P.A.Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
-
Patent number: 9585870Abstract: The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP levels, resulting in the release of calcium from the bone, which improves lactation.Type: GrantFiled: January 25, 2013Date of Patent: March 7, 2017Assignees: UNIVERSITY OF CINCINNATI, WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Nelson Horseman, Laura Hernandez Baumgard
-
Patent number: 9585871Abstract: The present invention encompasses methods of using fexinidazole to treat and eliminate and/or cure L. infantum infections in canines.Type: GrantFiled: January 31, 2014Date of Patent: March 7, 2017Assignee: MERIAL, INC.Inventors: Matthias Pollmeier, Jeffrey Lynn Blair
-
Patent number: 9585872Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: January 29, 2015Date of Patent: March 7, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Patent number: 9585873Abstract: A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).Type: GrantFiled: June 2, 2014Date of Patent: March 7, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marcus Stark, Ulrike D. Sent, Ingo Lang
-
Patent number: 9585874Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.Type: GrantFiled: January 6, 2016Date of Patent: March 7, 2017Assignee: Karyopharm Therapeutics Inc.Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
-
Patent number: 9585875Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.Type: GrantFiled: December 19, 2012Date of Patent: March 7, 2017Assignee: DOMPÉ FARMACEUTICI S.P.A.Inventors: Alessio Moriconi, Gianluca Bianchini, Sandro Colagioia, Laura Brandolini, Andrea Aramini, Chiara Liberati, Silvia Bovolenta
-
Patent number: 9585876Abstract: Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.Type: GrantFiled: March 13, 2014Date of Patent: March 7, 2017Assignee: NUSIRT SCIENCES, INC.Inventors: Michael Zemel, Antje Bruckbauer
-
Patent number: 9585877Abstract: A method of administering an effective amount of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.Type: GrantFiled: May 6, 2013Date of Patent: March 7, 2017Assignee: Forum Pharmaceuticals, Inc.Inventors: Dana C. Hilt, Gerhard Koenig
-
Patent number: 9585878Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: GrantFiled: August 9, 2010Date of Patent: March 7, 2017Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Liat Hayardeny
-
Patent number: 9585879Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.Type: GrantFiled: October 22, 2015Date of Patent: March 7, 2017Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
-
Patent number: 9585880Abstract: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18?) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl) amine structure.Type: GrantFiled: November 20, 2014Date of Patent: March 7, 2017Assignee: Universitetet I OsloInventors: Jo Klaveness, Kjetil Tasken
-
Patent number: 9585881Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: June 13, 2016Date of Patent: March 7, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
-
Patent number: 9585882Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: January 29, 2015Date of Patent: March 7, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
-
Patent number: 9585883Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.Type: GrantFiled: October 14, 2015Date of Patent: March 7, 2017Assignee: MYOKARDIA, INC.Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
-
Patent number: 9585884Abstract: The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: December 16, 2013Date of Patent: March 7, 2017Assignee: Auspex Pharmaceuticals, Inc.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Patent number: 9585885Abstract: [Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] The present invention provides a compound represented by the general formula (I): in which R1 is C1-6 alkyl or the like; R2 is hydrogen or the like; R3 and R4 are each hydrogen, C1-6 alkyl, R10R11N—C1-6 alkyl, aralkyl, or the like; R5 and R6 are hydrogen or the like; and R7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.Type: GrantFiled: December 6, 2013Date of Patent: March 7, 2017Assignee: KISSEI PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Nishimura, Yasunori Ueno, Kiyoshi Kasai, Masako Yoshida
-
Patent number: 9585886Abstract: This invention relates to pyrrolopyrimidine derivatives of formula (I): where R1, X, p, R4, R2 and R3 are as defined herein, and their use as pharmaceuticals.Type: GrantFiled: April 28, 2015Date of Patent: March 7, 2017Assignee: Calchan LimitedInventors: David R. Witty, David Norton, Jason Paul Tierney, Ghislaine Lorthioir, Mairi Sime, Karen Louise Philpott